alanylglutamine has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, J; Li, L; Ma, H; Ying, H; Zhao, Y; Zheng, Y | 1 |
| Li, L; Shi, J; Ying, H; Zhao, Y; Zheng, Y | 1 |
2 other study(ies) available for alanylglutamine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Alanyl-Glutamine Protects Mice against Methionine- and Choline-Deficient-Diet-Induced Steatohepatitis and Fibrosis by Modulating Oxidative Stress and Inflammation.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; Choline; Diet; Dipeptides; Fatty Acids; Glutathione Peroxidase; Inflammation; Lactate Dehydrogenases; Lipids; Liver; Liver Cirrhosis; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Racemethionine; Superoxide Dismutase | 2022 |
Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis.
Topics: Animals; Cholesterol; Diet, High-Fat; Dipeptides; Dysbiosis; Gastrointestinal Microbiome; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2023 |